GlaxoSmithKline pulls Imus advertising

Share this article:
GlaxoSmithKline has yanked its advertising from Don Imus’ talk show amid the controversy caused by remarks he made about the Rutgers University women’s basketball team. Imus’ show, a nationally syndicated radio program, is also simulcast on cable network MSNBC. According to TNS Media Intelligence, GlaxoSmithKline was the No. 5 advertiser on the MSNBC telecast of Imus’ show during 2006, spending $277,900. “The bottom line is that we have suspended our advertising with MSNBC until we can determine that we can have a level of confidence that our media standards are being adhered to,” GlaxoSmithKline spokeswoman Nancy Pekarek told MM&M. Pekarek said Glaxo did not buy any advertising space on Imus’ radio program. “What we did do was buy advertising on MSNBC. That put us on a rotation and that’s how the ads appeared on MSNBC in that time slot,” she said. Glaxo was among a number of companies that by Tuesday that had pulled their advertising from Imus’ show. Office supply chain Staples and consumer products manufacturer Procter & Gamble announced their intentions to pull their advertising from MSNBC in published reports. Another sponsor, Bigelow Tea, said in a posting on its Web site that Imus’ remarks have “put our future sponsorship in jeopardy.” Imus made his controversial comments during his show last week. He has been suspended for two weeks by MSNBC and CBS, which manages his radio broadcast. His suspension begins Monday. Reacting to mounting public pressure and the flood and cancelled sponsorships, MSNBC announced late Tuesday it has cancelled its simulcast of Imus' show.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...